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g.2012.0Abstract The molecular defects resulting in a b-thalassemia phenotype, in the Egyptian population
show a clear heterogenic pattern. Many studies have embarked on the molecular detection and
characterization of these mutations, using a wide array of the available techniques with successful
detection of both known and unknown mutations. PCR based techniques, as well as direct DNA
sequencing are effective with some limitations as regards the time, effort and high cost to reach a
ﬁnal diagnosis. Intermediary screening techniques have proved to be effective tools to overcome
these drawbacks. This study aims to assess the use of the denaturing gradient gel electrophoresis
(DGGE)1 to detect b-thalassemia mutations prior to the performance of direct sequencing to min-
imize the cost and workload involved in the process. In this study, forty-two previously genotyped
patients in a study by El-Gawhary et al. in 2007, have been analyzed by DGGE for fragment 2 then
1. These are the b-globin gene fragments showing the majority of the b-thalassemia mutations.
Sixty-eight alleles out of 79 mutant alleles in total were detected within these two fragments. The
11 undetected alleles comprise 9 alleles that require further examination using other DGGE frag-
ments (0, 4 and 5) and correspond to -87(C > G), intervening sequence (IVS)II-1(G > A), IVS
II-745, and IVS II-848(C > A). The remaining two that failed detection correspond to codon
(CD) 37(G > A). Although, IVS-II 745(C > G) is undetectable within these two fragments, its
100% linkage polymorphism (+20 C > T) was detected in fragment 1 gel. DGGE is a sensitiveEl-Sheikh Al-Khodary St.,
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.com, gme00@fayoum.edu.eg
ctrophoresis.
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344 G. Christopoulos et al.technique to screen for b-thalassemia mutations. For simultaneous analysis of multiple samples
with unknown mutations, it is recommended that direct DNA sequencing be coupled with DGGE
whenever available to reduce time, effort and cost.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
b-Thalassemia is the most common genetically inherited hemo-
globin disorder in Egypt with a carrier rate varying from 5.3 to
P9% as reported by a recent study [1]. This is a group of dis-
orders occurring almost entirely as a result of autosomal reces-
sive inheritance of 2 b-globin gene point mutations. However
small deletions of one to a few base pairs, as well as large dele-
tions affecting the b-globin gene cluster occurring commonly
in parts of the world, may cause this disorder. This genetic de-
fect results in reduced or absent synthesis of the b-globin chain.
Increasing research is accumulating hundreds of mutations
that are now known to cause this disease worldwide, with clus-
tering of few numbers of mutations for every community [2].
The study of this genetic heterogeneity in every population
has provided a new understanding of the disease phenotype,
guided the management of the disease, and allowed successful
prevention of the disease through prenatal diagnosis programs.
To date, the molecular characterization of the Egyptian
population has employed variable techniques for direct muta-
tion detection for known mutations and others for identiﬁca-
tion of unknown mutations. Polymerase chain reaction
(PCR) based techniques such as the ampliﬁcation refractory
mutation system (ARMS), the synthetic oligonucleotide
hybridization, the restriction enzyme digestion of the product
or the use of denaturant high performance liquid chromatog-
raphy (DHPLC) has greatly facilitated the screening for
known mutations [3–6]. Furthermore, the use of PCR ampliﬁ-
cation and direct sequencing has permitted the accurate char-
acterization of other unidentiﬁed alleles [6,7].
Although the automated ﬂuorescent capillary based DNA
sequencing is a very reliable method for the detection of un-
known mutations and/or polymorphisms, it is tedious, time
consuming as well as expensive. DGGE is considered one of
the most sensitive and speciﬁc mutational scanning techniques
[8]. Under appropriate conditions, all base pair substitutions,
frameshifts, and deletions less than 10 bp can be resolved from
the wild type sequence using DGGE [9].
The present study was performed to assess the usefulness of
DGGE as a screening technique for the detection of unknown
b-globin gene mutations in samples of known b-thalassemia
patients before direct DNA sequencing is performed. Thus
only a small area of the gene needs to be sequenced, therefore
reducing costs, time and workload.
2. Subjects and methods
Forty-two subjects were included in this study. These comprised
thirty-nine selected b-thalassemia patients (18 b-thalassemia
intermedia and 21 b-thalassemia major), one obligate b-thalas-
semia carrier, and two healthy controls. Selection of the patients
was done to include those having known genotypes previously
published by an earlier study [7] to allow objective evaluation
of DGGE when used to screen b-thalassemia mutations. Thegenotypes of the patients included the homozygous, the hetero-
zygous and the double heterozygous patterns (Table 1).
The subjects were comprised of 15 females and 27 males.
The patients’ ages ranged between 2 and 24 years, those with
b-thalassemia trait were 30 years old, while the two controls
were 24 and 26 years old, respectively.
2.1. Molecular studies
DGGE involves the electrophoresis of double stranded DNA
molecules through a polyacrylamide gel containing increasing
concentrations of denaturing agents such as formamide and
urea. The separation of the DNA fragments is based on the
melting properties of the DNA molecule which in turn is based
on the nucleotide sequence of the fragment under study. Dou-
ble stranded molecules differing by single base changes can
thus be separated, as they have different electrophoretic mobil-
ity as they undergo partial denaturation along the denaturant
gradient.
The DNA fragments from an individual heterozygous for a
mutation or polymorphism will show four bands on DGGE.
The two faster migrating bands are the homoduplexes corre-
sponding to the wild type and the mutant alleles. The addi-
tional bands that migrate at a slower rate in the gel consist
of the two heteroduplexes formed by re-sorting of strands dur-
ing PCR, which are less stable and melt out at a lower denatur-
ing condition (Fig. 1).
For DGGE analysis the b-globin gene is divided into 5 frag-
ments (Fig. 2). Analysis starts with fragments 1 and 2 where
the majority of mutations are located (Table 7). If no abnor-
mality is observed, analysis continues with fragments 0, 4
and 5 [4].
Genomic DNA was extracted from the peripheral blood
leucocytes of EDTA anticoagulated fresh blood using QIA-
amp DNA Blood Mini KitT from QIAGEN.
PCR ampliﬁcation was done for 2 b-globin gene fragments
using 2 sets of DGGE–PCR primers (Table 2) from Genosys
USA.
PCR reaction mix was done by adding 1.5 ll of extracted
DNA to the PCR master mix [5 ll of 10X buffer from GE
Healthcare, UK, 8 ll of 1.25 mM dNTPs from Invitrogen,
USA, 1 ll of each primer (25 pmol), 35 ll H2O, 0.3 ll AmpliT-
aq from GE Healthcare, UK (1.5 U) with a total of 51.8 ll in
each reaction]. The 10X buffer preparation is 500 mM KCl,
15 mM Mg Cl2, and 100 mM Tris–HCl (pH 9 at room temper-
ature). An initial denaturation was held at 94 C for 4 min.
This was followed by 40 cycles of denaturation at 94 C for
1 min, annealing at 60 C for 1.5 min and extension at 72 C
for 2 min. In the last cycle, extension was prolonged for
7 min. Ampliﬁed products of patients and controls were run
on 2% ethidium bromide agarose gel. The thermal cycler used
was an MJResearch PTC-100T (USA).
DGGE was performed for all patients and controls ﬁrst
examining PCR products for fragment 2. Fragment 1 PCR
Table 1 List of genotypes of patients and controls included in the study.
Patient genotype Number of patients (42)
-87(C > G)/-87(C > G) 3
IVS I-1(G > A)/IVS I-1(G > A) 4
IVS I-6(T > C)/IVS I-6(T > C) 15
IVS II-745(C > G)/IVS II-745(C > G) 4
CD 37(G> A)/CD 37(G> A) 1
CD 27(GCC> TCC)(Hb Knossos)/IVS I-1(G > A) 1
CD 27(GCC- > TCC)(Hb Knossos)/IVS I-6(T > C) 1
IVS I-1(G > A)/IVS I-6(T > C) 2
IVS I-110(G> A)/CD 27(GCC> TCC)(Hb Knossos) 1
IVS I-1(G>A)/IVS I-110(G>A) 1
CD 5(-CT)/IVS I-110(G>A) 1
IVS I-110(G>A)/IVS II-848(C>A) 1
IVS II-745(C>G)/IVS II-848(C>A) 1
IVS I-6(T>C)/IVS II-1(G>A) 1
IVS I-1(G>A)/IVS II-745(C>G) 1
IVS I-6(T>C)/IVS I-110(G>A) 1
IVS I-6(T>C)/N 1
N/N 2
Figure 1 Schematic diagram to show the principle of the DGGE
(provided by The Cyprus Institute of Neurology and Genetics
Thalassemia Group). WT: Wild type homoduplex–HET: Hetero-
zygous, the 2 faster migrating bands represent the wild and mutant
homoduplexes and the 2 slower bands represent the heteroduplex
bands of reassorted PCR strands–MUT: mutant homoduplex. The
mutant homoduplex on the actual gel may migrate faster or slower
than the wild type homoduplex and is determined by its melting
temperature.
Figure 2 Showing the ﬁve DGGE fragments of the b-globin gene
(provided by The Cyprus Institute of Neurology and Genetics
Thalassemia Group). Fragment 1 covers the promotor region and
ﬁrst exon. Fragment 2 covers the ﬁrst intron and the second exon.
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mutations (either one or both) were not detected by the ﬁrst
fragment.
DGGE was performed using a Bio-Rad DCode systemT
(Bio-Rad, USA). The polyacrylamide gel was prepared using
6% acrylamide/bisacrylamide 37.5:1 with a denaturing gradi-
ent of 35–75% urea and formamide. The loading buffer used
was ﬁcoll-400 bromophenol blue/xylene cyanol.
3. Theory of the study
Establishing an optimum protocol for the analysis of b-thalas-
semia mutations must be population targeted and accommo-
dated to the investigative facilities of different research
centers. The appropriate use of the widely available techniques
can improve the services, allowing better diagnosis and estab-
lishing successful disease prevention programs at an adequate
cost. b-Globin gene mutations span the entire coding as well as
non-coding regions. While whole genome sequencing is a
breakthrough in the sequencing technologies which highly in-
creases the through-put and reduces the cost of direct sequenc-
ing, yet automated ﬂuorescent capillary-based DNA
sequencing is still more widely available. The use of DGGE
is a widely accepted intermediate mutational screening tech-
nique, to facilitate analysis of large genes, and shows addi-
tional advantages in prenatal and pre-implantation genetic
diagnosis in b-thalassemia.
4. Results and discussion
The clinical groups of the patients in this study are mentioned
in Table 3.
The patients’ results were compared to a known normal as
well as a known heterozygous control for the IVS-1-110 muta-
tion which were run simultaneously with the patients’ ampli-
ﬁed products for fragment 2.
The results of the gel electrophoresis for fragment 2 PCR
products revealed 19 mutant homoduplex bands representing
the patients that carry homozygous mutations, seven double
Figure 3 From left to right: Lane 8 (sample No. 29): normal
control (previously genotyped). Lane 9 (sample No. 30): hetero-
zygous IVS-1-110 control (previously genotyped). Lanes 1, 3, 5, 6,
10, 11, 12, 13, 14: mutant homoduplex bands. Lane 2: double
heterozygous heteroduplex bands. Lanes 4 &7: heterozygous
heteroduplex bands. Lanes 15 & 16: normal homoduplex bands.
Table 4 The results of DGGE fragment 2 analysis for all
subjects included in the study.
DGGE analysis for PCR products No of patients %
Normal homoduplex 10 23.9
Double mutant heteroduplex 7 16.6
Normal homoduplex/mutant heteroduplex 6 14.3
Mutant homoduplex 19 45.2
Total subjects 42 100
Table 5 The results of DGGE fragment 1 analysis for normal
and heterozygous samples by fragment.
DGGE analysis for PCR products No of patients %
Normal homoduplex 9 56.25
Double mutant heteroduplex 0 0
Normal homoduplex/mutant heteroduplex 3 18.75
Mutant homoduplex 4 25
Table 2 Primer sets used for PCR for DGGE analysis.
DGGE-Fragment Primer- direction Primer sequence
Fragment 1
(300 bp)
Forward primer 5’ CGC CCG CCC CGC CCC CGT GCC CCC CGC GCC CGC CCC GCC
CCC GTA CGG CTG TCA TCA CTT AGA CCT CA 3’
Fragment 1 Reverse primer 5’ CAA CTT CAT CCA CGT TCA CC 3’
Fragment 2
(420 bp)
Forward primer 5’ GGT GAA CGT GGA TGA AGT T 3’
Fragment 2 Reverse primer 5’ GCG GGC GGG GCG GGG GCA CGG GGG GCG CGG CGG GCG
GGG CGG GGG TGC AGC TTG TCA CAG TGC AGC TCA CT 3’
Table 3 Clinical groups of b-thalassemia patients included in
the study.
Group Clinical presentations No of patients
A Healthy controls 2
B Obligatory carrier 1
C b-Thalassemia intermedia 18
D b-Thalassemia major 21
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double heterozygous b-thalassemia mutations, six normal/mu-
tant heteroduplex bands representing the patients heterozy-
gous for one b-thalassemia mutation detectable within this
fragment (Fig. 3). The remaining ten samples showed normal
homoduplex bands representing patients that have no muta-
tions/polymorphisms detectable within the tested fragment
(Table 4) .The latter 10 patients as well as the six heterozygous
patients (16 in all) were subjected to fragment 1 DGGE anal-
ysis. Their DGGE–PCR products were compared to those of aknown normal control as well as a known heterozygous con-
trol for silent CD2 polymorphism. Results showed four mu-
tant homoduplex bands, three normal/mutant heteroduplex
bands and nine normal homoduplex bands (Table 5).
Since DGGE is only a screening technique to detect the
presence of the mutation in a speciﬁc DNA fragment, these re-
sults cannot be considered conclusive as to the type of the
mutation until direct DNA sequencing is performed.
Therefore after analysis of eighty-four chromosomes of all
patients, controls and one carrier, by fragments 2 and 1 of
the b-globin gene, 68 mutant alleles out of seventy-nine
(86.0759%) were detected, whereas 11 mutant alleles
(13.924%) remained undetected within these 2 fragments and
require further screening by other DGGE fragments (Fig. 4).
Out of the 68 detected mutant alleles 46 belong to 23 patients,
in whom both the mutations were detected within these 2 frag-
ments and therefore need no further screening for their sam-
ples by other DGGE fragments (0, 4 and 5) (Fig. 5). The
results of the DGGE were then compared with the genotypes
of the patients (Table 6). The undetected alleles were found
to correspond to the following mutations: -87, IVS II-1, IVS
II-745, IVS II-848, CD 37. The 100% linked polymorphism
(+20 C > T) to the IVS II-745, and not the mutation itself,
was detected as it lies in the 5’ untranslated region of the gene
(an area covered by fragment 1).
Figure 4 Results of chromosome analysis by fragments 1 &2.
Undetected mutant alleles represent approximately 14% of the
total.
Figure 5 Results. After analysis by fragments 1 & 2, twenty-
three patients showed complete results. Sixty-eight alleles were
detected while eleven alleles were not detected from a total of
seventy-nine.
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anemia in Egypt. It remains a major public health problem.
Studies on the Egyptian population have shown a few common
mutations plus a wide range of less common mutations. In this
study we aim to show the result of employing denaturing
gradient gel electrophoresis technique to localize the b-
thalassemia mutations in a group of Egyptian patients. Two
b-globin gene fragments, denoted fragments 1 and 2, were
ampliﬁed by DGGE–PCR primers and then analyzed by
DGGE for samples of 39 patients, two healthy controls andTable 6 Comparison between patient genotypes and results of DG
Patient genotype Fragment 2
-87/-87 Normal homod
IVS I-1/IVS I-1 Mutant homod
IVS I-6/IVS I-6 Mutant homod
IVS II-745/IVS II-745 Normal homod
CD 37/CD 37 Normal homod
CD 27(Hb Knossoss)/IVS I-1 Double mutant
CD 27(Hb Knossoss)/IVS I-6 Double mutant
IVS I-1/IVS I-6 Double mutant
CD 27(Hb Knossoss)/IVS I-110 Double mutant
IVS I-1/IVS I-110 Double mutant
CD 5 –CT/IVS I-110 Normal/mutant
IVS I- 110/IVS II-848 Normal/mutant
IVS II-745/IVS II-848 Normal homod
IVS I-6/IVS II-1 Normal/mutant
IVS I-1/IVS II-745 Normal/mutant
IVS I-6/IVS I-110 Double mutant
IVS I-6/N Normal/mutant
N/N Normal homod1 b-thalassemia trait individual, with a total of 42 subjects
and 84 chromosomes of previously identiﬁed genotypes[7].
These 2 fragments are known to show the majority of b-
thalassemia mutations (Table 7). Using these 2 fragments, 68
(68.0759%) mutant alleles were detected, while the remaining
11 (13.924%) mutant alleles were undetected. By comparing
the latter alleles to their genotypes they were found to corre-
spond to -87, IVS II-1, IVS II-745, IVS II-848, and CD 37.
Theoretically, CD 37 should be detected by DGGE fragment
2. The other mutations require further analysis by the other
DGGE fragments which are known to show the less com-
monly occurring b-thalassemia mutations in the Mediterra-
nean region (refer to Fig. 2). Mutations within the second
intron (fragment 3) are not possible to detect as it harbors a
number of polymorphisms which distorts the results [4]. Dur-
ing each DGGE run, both a normal control known to carry
the wild type gene as well as a known heterozygous control
which is detectable within the chosen gene fragment are in-
cluded. These controls assess the validity and performance of
the technique [8], and for expert hands the heterozygous con-
trol may give a clue about similar mutations/polymorphisms
when run simultaneously on the same gel. Although this is
an obvious advantage, all samples must be sequenced to iden-
tify the type of mutation involved. Failure to detect mutations
may also be due to Taq induced errors which may reduce the
sensitivity of the DGGE system [9]. Experimental determina-
tion of optimal electrophoresis conditions allows maximum re-
trieval of results [8,10].
A study carried out for the molecular characterization of b-
thalassemia in Egypt, using PCR ampliﬁcation and restriction
site analysis followed by DGGE and direct sequencing was
able to detect twelve different mutations in the Suez Canal area
[6].
A large study on 118 patients identiﬁed the largest spectrum
of b-thalassemia mutations so far reported in Tunisia (18 dis-
tinct mutations), using a combination of several PCR based
techniques, DGGE and direct nucleotide sequencing [11].
Another study was done for the molecular characterization
of b-thalassemia in Syria, that used gene ampliﬁcation with
speciﬁc oligonucleotide primers, enzyme analysis, denaturingGE.
Fragment 1
uplex Normal homoduplex
uplex Not done
uplex Not done
uplex Mutant homoduplex
uplex Normal homoduplex
heteroduplex Not done
heteroduplex Not done
heteroduplex Not done
heteroduplex Not done
heteroduplex Not done
heteroduplex Normal/mutant heteroduplex
heteroduplex Normal homoduplex
uplex Normal/mutant heteroduplex
heteroduplex Normal homoduplex
heteroduplex Normal/mutant heteroduplex
homoduplex Not done
heteroduplex Normal homoduplex
uplex Normal homoduplex
Table 7 Some b-globin gene mutations and polymorphisms that can be
detected by DGGE fragments 1 & 2.
Fragment 1 Fragment 2
30(T>A/C) IVS I-1(G>A)
+20* (C > T)polymorphism IVS I-5(G > A/T)
+33(C > G) IVS I-6(T > C)
CD 2(CAC> CAT)polymorphism IVS I-110(G > A)
FSC-5(–CT) IVS I-116(T > G)
Hb-S(GAG>GTG) IVS I-130(GC/A)
Frameshift(FSC)-6 –A CD 25/26(+T)
FSC-8(–AA) CD 27(GCC> TCC) Hb Knossos
FSC-8/9(+G) CD 36/37(T)
CD 15(TGG> TGA) CD 37(TGG> TGA)
CD 22/23/24 del –AAGTTGG CD 39(CAG> TAG)
CD 37/38/39–GACCCAG
CD 44(C)
* 100% linkage polymorphism cis to the IVS II-745.
348 G. Christopoulos et al.gradient gel electrophoresis and direct sequencing. By combin-
ing these three approaches, seventeen different mutations were
identiﬁed, with successful mutation detection in almost 90% of
the chromosomes studied [4].
A study was done including 95 Egyptian thalassemic pa-
tients, and used PCR–ARMS complemented by direct DNA
sequencing for the detection of common and uncharacterized
mutations. Combining these two techniques, mutations of all
patients were fully characterized [7].
A recent study carried out on 172 patients from Western
Saudi Arabia, which used PCR-ARMS and direct DNA
sequencing, successfully identiﬁed 23 b-thalassemia mutations
[12].
The discrepancy between the above studies, as regards the
approaches used in the molecular characterization of b-thalas-
semia alleles in different populations, with or without applying
DGGE as a screening technique for unknown mutations be-
fore DNA sequencing, may be attributed to the question of
availability of this technique in different research laboratories.
5. Conclusion
Although it is equally reliable to detect b-thalassemia muta-
tions using DNA sequencing, both common as well as rare
ones, without prior DGGE analysis of samples, the cost can
be signiﬁcantly higher. In smaller or lower budget centers with
more limited resources, cost and workload reduction is of es-
sence. Therefore the application of a fast accurate and cheap
technique can make a big difference and improve services.
The use of DGGE as an intermediate technique is excellent
for that purpose, particularly when multiple samples are simul-
taneously analyzed. The recommended approach is ﬁrst to use
one or more of the PCR-based techniques, to detect common
mutations, followed by denaturing gradient gel electrophoresis
[4,6,11], or other mutational screening techniques [13,14], and
DNA sequencing for detection of rare ones. The use of DGGE
has an added advantage in the prenatal diagnosis of b-thalas-
semia [15]. Once the mutations are characterized, testing other
family members and prenatal tests are much simpler. DGGE
also has a wide application in PGD2 as it facilitates simulta-2 PGD2: preimplantation genetic diagnosisneous analysis of more than one mutation in a single PCR
fragment; it detects the presence of normal alleles and moni-
tors the occurrence of allelic drop-out through the expectation
that heterozygous samples have more than one electrophoretic
band on analysis [16].
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